Moors & Cabot Inc. Buys 15,600 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

Moors & Cabot Inc. raised its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 137.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 26,969 shares of the company’s stock after buying an additional 15,600 shares during the period. Moors & Cabot Inc.’s holdings in MaxCyte were worth $124,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in MXCT. Harbor Capital Advisors Inc. acquired a new position in shares of MaxCyte in the 2nd quarter valued at about $26,000. Quantbot Technologies LP acquired a new position in shares of MaxCyte in the 2nd quarter valued at about $27,000. Tower Research Capital LLC TRC lifted its stake in shares of MaxCyte by 139.8% in the 1st quarter. Tower Research Capital LLC TRC now owns 7,108 shares of the company’s stock valued at $35,000 after purchasing an additional 4,144 shares during the period. Cubist Systematic Strategies LLC lifted its stake in shares of MaxCyte by 5,302.5% in the 1st quarter. Cubist Systematic Strategies LLC now owns 12,750 shares of the company’s stock valued at $63,000 after purchasing an additional 12,514 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of MaxCyte in the 2nd quarter valued at about $76,000. Institutional investors own 62.25% of the company’s stock.

MaxCyte Stock Performance

MXCT stock opened at $4.50 on Tuesday. The stock’s 50 day simple moving average is $3.25 and its 200 day simple moving average is $3.93. MaxCyte, Inc. has a fifty-two week low of $2.45 and a fifty-two week high of $6.43. The company has a market cap of $466.09 million, a P/E ratio of -12.16 and a beta of 0.84.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Stephens reaffirmed an “overweight” rating and set a $12.00 price target on shares of MaxCyte in a research note on Thursday, October 5th. William Blair reaffirmed an “outperform” rating on shares of MaxCyte in a research note on Thursday, November 9th.

Insiders Place Their Bets

In other MaxCyte news, Director John Joseph Johnston sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $3.71, for a total transaction of $37,100.00. Following the completion of the sale, the director now directly owns 120,583 shares of the company’s stock, valued at approximately $447,362.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 12,941 shares of company stock valued at $47,982. Corporate insiders own 6.00% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.